FP046A PHASE 2 DOSE-RANGING STUDY COMPARING PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD), AND TOLERABILITY OF MODIFIED RELEASE (MR) VS IMMEDIATE RELEASE (IR) TOLVAPTAN (TLV) IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS (PT)

Autosomal Dominant ◽

Immediate Release ◽

Phase 2 ◽

Modified Release ◽

Polycystic Kidney ◽

Dose Ranging ◽

FP045NOCTURNE: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO COMPARE TOLVAPTAN (TLV) MODIFIED-RELEASE (MR) AND IMMEDIATE-RELEASE (IR) FORMULATIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS (PT)

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfz106.fp045 ◽

2019 ◽

Vol 34 (Supplement_1) ◽

Author(s):

Ronald Perrone ◽

Arlene Chapman ◽

Dorothee Oberdhan ◽

Frank S Czerwiec ◽

Olga Sergeyeva ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Controlled Trial ◽

Immediate Release ◽

Phase 2 ◽

Modified Release ◽

Polycystic Kidney ◽

FP806INITIAL RESULTS FROM A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND IGA NEPHROPATHY

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy146.fp806 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i635-i635

Author(s):

Pablo Pergola ◽

Gerald Appel ◽

Ahmed Awad ◽

Geoffrey Block ◽

Melanie Chin ◽

...

Keyword(s):

Kidney Disease ◽

Iga Nephropathy ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

High Versus Ad Libitum Water Intake in Patients with Autosomal Dominant Polycystic Kidney Disease (DRINK): An Open Label, Randomised Controlled Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3294762 ◽

2018 ◽

Author(s):

Ragada El-Damanawi ◽

Michael Lee ◽

Tess Harris ◽

Laura B. Mader ◽

Simon Bond ◽

...

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Open Label ◽

Phase 2 Trial ◽

Ad Libitum ◽

Autosomal Dominant Polycystic Kidney ◽

Randomised Controlled

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

The Journal of Clinical Pharmacology ◽

10.1002/jcph.880 ◽

2017 ◽

Vol 57 (7) ◽

pp. 906-917 ◽

Cited By ~ 12

Author(s):

Susan E. Shoaf ◽

Arlene B. Chapman ◽

Vicente E. Torres ◽

John Ouyang ◽

Frank S. Czerwiec

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Pharmacokinetics And Pharmacodynamics ◽

Dose Selection ◽

Phase 3 ◽

Pivotal Phase ◽

Echocardiographic findings in kidney transplant patients with autosomal dominant polycystic kidney disease

Scandinavian Journal of Urology and Nephrology ◽

10.1080/00365590902972446 ◽

2009 ◽

pp. 1-4

Author(s):

Henrik Hadimeri ◽

Kenneth Caidahl ◽

Odd Bech-Hanssen ◽

Gudrun Nyberg

Keyword(s):

Kidney Disease ◽

Kidney Transplant ◽

Autosomal Dominant ◽

Polycystic Kidney ◽

Transplant Patients ◽

Kidney Transplant Patients ◽

Autosomal Dominant Polycystic Kidney ◽

Echocardiographic Findings

Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging

Praxis ◽

10.1024/1661-8157/a002890 ◽

2018 ◽

Vol 107 (3) ◽

pp. 158-164

Author(s):

Andreas D. Kistler ◽

Gustav Andreisek

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Polycystic Kidney ◽

Prognostic Evaluation ◽

328 Utilization of Radiographic Imaging in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2019.03.330 ◽

2019 ◽

Vol 73 (5) ◽

pp. 729

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Radiographic Imaging ◽

Polycystic Kidney ◽

405 Geographic Distribution in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A US Population-based Study

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2020.02.407 ◽

2020 ◽

Vol 75 (4) ◽

pp. 654-655

Keyword(s):

Kidney Disease ◽

Geographic Distribution ◽

Autosomal Dominant ◽

Population Based ◽

Polycystic Kidney ◽

Population Based Study ◽

Proteinuria in children with autosomal dominant polycystic kidney disease

Minerva Pediatrica ◽

10.23736/s0026-4946.16.04404-2 ◽

2018 ◽

Vol 70 (5) ◽

Author(s):

Tomáš Seeman ◽

Michael Pohl ◽

Ulrike John

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Polycystic Kidney ◽

Faculty Opinions recommendation of Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1156979.617056 ◽

2009 ◽

Author(s):

Ron Gansevoort ◽

Ester Meijer

Keyword(s):

Kidney Disease ◽

Autosomal Dominant ◽

Kidney Volume ◽

Polycystic Kidney ◽